PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

The conserved intermolecular hydrogen bonds of PD-1 Y68 with PD-L1 D122 and of PD-1 K78 and PD-L1 F19 are indicated by dashed lines. Credit: Frontiers in Immunology (2025). DOI: 10.3389/fimmu.2025 ...

Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor prognosis. Although the addition of anti-PD(L)1 ...

Additionally, six PD-L1–resistant patients with stable disease remain on treatment past 12 or more weeks, with tumor reductions ranging from 0% to 17%, suggesting durable disease control in a subset ...

PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.

Established market size for PD-1 and PD-L1 checkpoint inhibitor antibodies; Business deals with economic terms: spin-offs, financing, licensing; mergers & acquisitions, company valuation.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...

The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.

In PD-L1-negative patients, the size of improvement fell to just 8% versus chemo alone. The death-risk reduction in the all-comers population, at 20%, met statistical significance.

Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year. By James Waldron Jul 30, 2024 8:14am. Incyte PD-L1 checkpoint inhibitors solid tumor. For ...

Serial sections of 100 resected GC samples, with PD-L1 expression levels across the dynamic range, were stained with three in vitro diagnostic-grade PD-L1 assays (28-8, 22C3, and SP263). Three trained ...